Straits Times Index
3,296.89 +4.20 (+0.13%) S&P 500
5,064.20 +45.81 (+0.91%) Dow
38,225.66 +322.37 (+0.85%) Nasdaq
15,840.96 +235.48 (+1.51%) Bitcoin USD
59,350.98 +1,408.67 (+2.43%) CMC Crypto 200
1,277.08 +6.34 (+0.50%)
Moderna, Inc. (0QF.MU)
- Yahoo Finance Video
Novo Nordisk slides while Moderna pops: Tale of two pharma stocks
Pharmaceutical stocks Novo Nordisk (NVO) and Moderna (MRNA) are trending in opposite directions following their earnings reports. Despite topping Wall Street's profit expectations, Novo Nordisk shares are sinking as the company fell short of estimates for its popular GLP-1 weight-loss drug, Wegovy. Meanwhile, Moderna is on the rise even after reporting first quarter losses. Moderna's growth is largely due to an uptick in coronavirus boosters and an expansion into the Brazillian market. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Melanie Riehl
- Yahoo Finance Video
Moderna CEO on the changing COVID market: Pandemic to endemic
Shares of pharmaceutical company Moderna (MRNA) are on the rise despite first quarter losses. Moderna CEO Stéphane Bancel tells Yahoo Finance Senior Reporter Anjalee Khemlani that the company is busy developing updated coronavirus vaccines for the 2024-2025 season and recently announced an expansion into the Brazilian market. As the coronavirus pandemic has shifted toward an endemic, Bancel explains how Moderna continues to innovate, sharing a positive outlook on phase two data for a combination flu and coronavirus vaccine. For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Melanie Riehl
- Benzinga
Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025 Formula, Stock Soars
Thursday, Moderna Inc (NASDAQ:MRNA) reported a first-quarter EPS loss of $(3.07), down from an income of $(0.19), smaller than the consensus estimate loss of $(3.55). The company reported sales of $167 million, sharply below $1.9 billion a year ago due to evaporating COVID-19 vaccine sales, beating the consensus of $97.5 million. The company cut research and development expenses by 6% in the quarter, mainly due to the absence of upfront collaboration payments. Moderna added that clinical develop
